Table 1.
Baseline characteristics prior to receiving amubarvimab/romlusevimab (A/R) or placebo.
| A/R (n = 390) | Placebo (n = 390) | Total (n = 780) | |
|---|---|---|---|
| Country of enrollment | |||
| United States | 251 (64%) | 261 (67%) | 512 (66%) |
| South Africa | 72 (18%) | 59 (15%) | 131 (17%) |
| Argentina | 49 (13%) | 49 (13%) | 98 (13%) |
| Brazil | 15 (4%) | 18 (5%) | 33 (4%) |
| Mexico | 3 (1%) | 2 (1%) | 5 (1%) |
| Philippines | 0 (0%) | 1 (<1%) | 1 (<1%) |
| Age, median (quartiles) years | 48 (39, 58) | 49 (39, 59) | 49 (39, 58) |
| Female sex, n (%) | 200 (51%) | 206 (53%) | 406 (52%) |
| Cis-gender, n (%) | 390 (100%) | 388 (99%) | 778 (>99%) |
| Race, n (%) | |||
| White | 275 (71%) | 289 (74%) | 564 (72%) |
| Black or African American | 80 (21%) | 61 (16%) | 141 (18%) |
| Asian | 16 (4%) | 21 (5%) | 37 (5%) |
| American Indian or Alaska Native | 0 (0%) | 1 (<1%) | 1 (<1%) |
| Native Hawaiian or Other Pacific Islander | 1 (<1%) | 1 (<1%) | 2 (<1%) |
| Multiple | 4 (1%) | 2 (1%) | 6 (1%) |
| Other | 14 (4%) | 15 (4%) | 29 (4%) |
| Hispanic/Latino ethnicity, n (%) | 192 (49%) | 190 (49%) | 382 (49%) |
| BMI (kg/m2), median (quartiles) | 29.5 (25.8, 35.3) | 30.0 (26.1, 36.1) | 29.8 (26.0, 35.9) |
| Cigarettes smoking statusa | |||
| Current | 105 (27%) | 112 (29%) | 217 (28%) |
| Former | 54 (14%) | 54 (14%) | 108 (14%) |
| Never | 231 (59%) | 223 (57%) | 454 (58%) |
| Reporting >1 high-risk co-morbidity, n (%)b | 364 (93%) | 366 (94%) | 730 (94%) |
| SARS-CoV-2 Vaccination, n (%)c | 30 (8%) | 40 (10%) | 70 (9%) |
a
Excludes 1 placebo participant with a missing value.
b
High Risk Comorbidities include active cancer, moderate to severe asthma, chronic kidney disease, chronic liver disease, history of cirrhosis, chronic lung disease, current smoker, cardiovascular disease, diabetes, hypertension, treatment with biologics/immunomodulators/cancer chemotherapy within 90 days of entry, HIV with CD4 count <200 cells/mm³, receiving corticosteroids within 30 days of entry, and obesity.
c
Defined as having received at least 1 dose of COVID-19 vaccine regardless of brand.